APRE vs EFX · $10.4M cap vs P/E 54, rev $5.68B
Aprea Therapeutics Inc (APRE) versus Equifax Inc (EFX) — a side-by-side from cached financials, not a winner call.
Aprea Therapeutics Inc (APRE) is a biotechnology company listed on US.
Equifax Inc (EFX) is a consulting services company listed on US.
APRE does not have a complete income-statement cache yet.
Latest reported EFX revenue for 2024-12-31 was $5.68B. Net income was $607.3M. Revenue was up 7.9% from 2023-12-31 to 2024-12-31. EFX currently screens at market cap $33.00B and trailing P/E 54.0.
APRE currently screens at market cap $10.4M. EFX currently screens at market cap $33.00B and trailing P/E 54.0.
Not investment advice. Open the APRE and EFX stock pages for the full models.
Not investment advice.